Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-Targeted CAR-T in Relapsed/Refractory ALL
NCT03544021Phase 2Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sino19 in acute lymphoblastic leukemia (ALL), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoints: Dose-limiting toxicity at 28 days, Incidence of adverse events at 3 months and 1 more. Status: unknown.
02
Drugs
Sino19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03544021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544021.